Certara initiated with a Market Perform at JMP Securities

JMP Securities initiated coverage of Certara with a Market Perform rating and no price target. Certara is a leading provider of model-informed drug development software and tech-enabled services to biopharma companies, the analyst tells investors in a research note. The firm likes the company’s competitive positioning and reputation as an essential partner to biopharma companies, but is cautious given decelerating clinical trial initiations across 2022 and 2023, and more modest biopharma capital markets activity during the same timeframe.